PIM
JAZZ icon

Partner Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Partner Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,027
Closed -$2.36M – 106
2018
Q3 		$2.36M Sell
14,027
-3,307
-19% -$569K 1.81% 13
2018
Q2 		$2.99M Buy
17,334
+1,796
+12% +$294K 2.41% 6
2018
Q1 		$2.35M Buy
+15,538
New +$2.28M 2.53% 8
2017
Q2 		– Sell
-15,857
Closed -$2.3M – 97
2017
Q1 		$2.3M Sell
15,857
-2,489
-14% -$324K 2.8% 4
2016
Q4 		$2M Sell
18,346
-3,045
-14% -$339K 2.65% 8
2016
Q3 		$2.6M Buy
21,391
+11,182
+110% +$1.51M 3.85% 2
2016
Q2 		$1.44M Sell
10,209
-5,127
-33% -$756K 2.36% 12
2016
Q1 		$2M Buy
15,336
+4,292
+39% +$534K 3.26% 8
2015
Q4 		$1.55M Buy
11,044
+2,908
+36% +$403K 2.55% 12
2015
Q3 		$1.08M Sell
8,136
-777
-9% -$134K 1.63% 21
2015
Q2 		$1.57M Sell
8,913
-937
-10% -$168K 2.21% 13
2015
Q1 		$1.7M Buy
+9,850
New +$1.69M 2.56% 7

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Partner Investment Management's JAZZ Position: Q4 2018 in Review

Partner Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 14,027 shares — an estimated $2.36M sold.

Partner Investment Management first reported a position in JAZZ in Q1 2015 and held it in 12 quarters. The position peaked at $2.99M in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Partner Investment Management reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Partner Investment Management sold 14,027 Jazz Pharmaceuticals shares in Q4 2018, an estimated $2.36M.
  • Partner Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Partner Investment Management's Jazz Pharmaceuticals position peaked at $2.99M in Q2 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Partner Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.